Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 102.51 -0.29 (-0.28%)
price chart
Johnson & Johnson Names New Chairman
William C. Weldon, the chairman of Johnson & Johnson, is stepping down at the end of this year and will be succeeded by Alex Gorsky, the current chief executive, the company announced Friday.
Johnson & Johnson Elects CEO Gorsky Chairman  Fox Business
Weldon passes baton at Johnson & Johnson to Gorsky  Bizjournals.com
Related articles »  
Dr. Buffett Has Diagnosed Johnson & Johnson As Too Big To Succeed
We are amazed that Johnson & Johnson's (NYSE:JNJ) shares have held up better than the S&P 500 over the last month.
Johnson & Johnson, Merck and Eli Lilly to rip red tape from clinical trials
Johnson & Johnson's ($JNJ) Janssen R&D unit is leading a charge to expedite the tedious process of selecting sites for clinical trial sites, with the creation of a investigator database intended to get studies up and running more efficiently.
J&J, Lilly, Merck plan clinical trial site database  Reuters
Janssen Forms �Investigator Databank� to Help Streamline Drug Trials  Xconomy
Related articles »  
Warren Buffett Buys More Wells Fargo and IBM, Sells Johnson & Johnson
But Warren Buffett did buy more of his favorite companies Wells Fargo and IBM, and sold Johnson & Johnson during the third quarter.
Warren Buffett Buys Deere and Wabco; Sells Johnson & Johnson and P&G  ValueWalk
Buffett's Significant Changes To Berkshire Hathaway Stock Holdings  24/7 Wall St.
Related articles »  
J&J says it won't enforce AIDS drug patent in Africa
LONDON (Reuters) - Generic manufacturers are to be given a free rein to make cheap copies of Johnson & Johnson's HIV/AIDS drug Prezista for sale in Africa and other poor countries.
Related articles »  
Johnson & Johnson One-Ups Tuberculosis
In an 18-0 ruling on efficacy, the FDA advisory committee voted in favor of Johnson & Johnson's bedaquiline, a drug to combat multidrug-resistant tuberculosis.
Related articles »  
Insurance And Income: Protecting Johnson & Johnson
In our previous article we discussed our observations about the difficulties insuring stock positions that pay a high dividend yield.
Amgen, Johnson & Johnson, Bernstein Litowitz, and the fraud on the market theory
You might remember that the Center for Class Action Fairness objected to a $0 settlement in Johnson & Johnson. The objector argued that the settlement provided no benefit to shareholders.
Johnson & Johnson Campaign for Nursings Future turns 10
Ten years ago a nursing shortage loomed in the United States. A shortfall of about 400,000 nurses by 2020 was projected and, between 1983 and 1998, the proportion of RNs younger than 30 had dropped from 30% to 12%, according to a 2000 article in the ...
Related articles »  
Buy Johnson & Johnson For Rock Solid Dividends - No Capital Appreciation ...
Johnson & Johnson (NYSE:JNJ) operates under three segments: Pharmaceutical (eighth largest in the world), Medical Devices and Diagnostic (the largest in the world) and Consumer (6th largest in the world).